Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Ann Surg Oncol. 2011 Sep;18(9):2579-84. doi: 10.1245/s10434-011-1655-x. Epub 2011 Mar 16.
(18)F-fludeoxyglucose (FDG) positron emission tomography (PET) is a sensitive and specific method for detecting active residual disease after chemoradiotherapy or radiotherapy, but few studies have accurately evaluated its diagnostic accuracy with histopathologic correlation. We therefore investigated the clinical utility of (18)F-FDG PET/computed tomography (CT) in patients undergoing salvage surgery for residual head and neck squamous cell carcinoma (HNSCC) after primary nonsurgical treatments.
Thirty-nine patients who initially received chemotherapy (n = 23), radiotherapy (n = 3), or chemoradiotherapy (n = 13) were evaluated 8-28 weeks later by (18)F-FDG PET/CT and CT/magnetic resonance imaging (MRI) prior to salvage surgery to clear residual disease. These results were compared with those of histopathologic analysis of the primary tumor and neck dissection tissue samples.
Of these 39 patients, 22 (56%) had residual primary tumor. The sensitivity, specificity and accuracy of (18)F-FDG PET/CT for detecting primary tumors were 91, 65, and 79%, respectively. Of 56 dissected heminecks, 37 (66%) had residual metastatic lymph nodes. (18)F-FDG PET/CT and CT/MRI had accuracies for positive heminecks of 91 and 75%, respectively (P = 0.004). On a cervical level-by-level-based analysis, (18)F-FDG PET/CT and CT/MRI had accuracies of 89 and 78%, respectively (P < 0.001); (18)F-FDG PET/CT had a specificity of 93% and a negative-predictive value of 92% for detection of positive levels.
(18)F-FDG PET/CT is superior to CT/MRI in detecting residual nodal disease in head and neck squamous cell carcinoma patients undergoing salvage surgery. Accurate preoperative diagnosis using (18)F-FDG PET/CT may help to determine the extent of salvage surgery.
(18)F-氟代脱氧葡萄糖(FDG)正电子发射断层扫描(PET)是一种用于检测放化疗后活性残留疾病的敏感和特异的方法,但很少有研究通过组织病理学相关性准确评估其诊断准确性。因此,我们研究了(18)F-FDG PET/CT 在头颈部鳞状细胞癌(HNSCC)患者接受挽救性手术后残留疾病的临床应用。
39 例患者最初接受化疗(n=23)、放疗(n=3)或放化疗(n=13),在挽救性手术前 8-28 周进行(18)F-FDG PET/CT 和 CT/磁共振成像(MRI)评估,以清除残留疾病。这些结果与原发肿瘤和颈部解剖组织样本的组织病理学分析结果进行比较。
39 例患者中,22 例(56%)有残留原发性肿瘤。(18)F-FDG PET/CT 检测原发性肿瘤的敏感性、特异性和准确性分别为 91%、65%和 79%。56 个被解剖的半颈中,37 个(66%)有残留的转移性淋巴结。(18)F-FDG PET/CT 和 CT/MRI 对半颈阳性的准确率分别为 91%和 75%(P=0.004)。在基于颈椎水平的分析中,(18)F-FDG PET/CT 和 CT/MRI 的准确率分别为 89%和 78%(P<0.001);(18)F-FDG PET/CT 对阳性水平的检测特异性为 93%,阴性预测值为 92%。
(18)F-FDG PET/CT 优于 CT/MRI 检测头颈部鳞状细胞癌患者挽救性手术后残留淋巴结疾病。使用(18)F-FDG PET/CT 进行准确的术前诊断可能有助于确定挽救性手术的范围。